We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Sign in
Sign in
Companies → MOREPEN LABORATORIES LIMITED
Save to list
Remove

MOREPEN LABORATORIES LIMITED

India, Haryana, Gurugram
Report a bug?
Claim ownership and edit
Description
India-based Morepen Laboratories manufactures and markets generic drugs in more than 50 countries. The company is one of the top global producers of generic Loratadine, an antihistamine. It supplies Loratadine to pharmaceutical companies such as Merck and Novartis. With generics currently in place for sleeping aids, digestive aids, analgesics, and dietary supplements, Morepen Laboratories intends to focus on a few select therapeutic segments for future contract manufacturing, such as asthma, neuropsychiatry, allergies, and diabetes. The company was founded in 1984.
Industries
SIC
Address:

2nd Floor

Tower C

DLF Cyber Park Udyog Vihar-III

Sector 20 Gurugram

Haryana

122016 India

Website:
Revenue
Recent news:

Energy & Utilities Roundup: Market Talk

Find insight on Infratil, oil futures and more in the latest Market Talks covering Energy and Utilities.

Source: The Wall Street Journal Sep 9, 2025

Westin Desaru Coast Resort partners with CAYIN Technology for digital signage

The partnership involves the implementation of the CMS-WS server and CAYIN Signage Player.

Source: Hotel Management Network Sep 9, 2025

Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes

India's benchmark Nifty 50 closed higher for a fifth consecutive session on Tuesday, with gains led by information technology stocks on Infosys' share buyback plan and U.S. interest rate cut prospects. The Nifty 50 and the BSE Sensex gained 0.39% each to 24,868.6 and 81,101.32 points, respectively. IT jumped 2.8%, led by a 5% surge in Infosys after it announced plans to consider a share buyback on September 11.

Source: Reuters Sep 9, 2025

Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/21/2026
Market Cap: 20.28 B
Enterprise Value: 20.93 B
Trailing P/E: 20.55
Forward P/E: N/A
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 1.14
Price/Book (mrq): 1.69
Enterprise Value/Revenue: 1.18
Enterprise Value/EBITDA: 11.24
Financial Highlights
Profitability and Income Statement
Profit Margin: 5.57%
Return on Assets (ttm): 3.49%
Return on Equity (ttm): 8.62%
Revenue (ttm): 17.87 B
Net Income Avi to Common (ttm): 994.48 M
Diluted EPS (ttm): 1.80
Balance Sheet and Cash Flow
Total Cash (mrq): 808.74 M
Total Debt/Equity (mrq): 13.24%
Levered Free Cash Flow (ttm): -2.74 B
Company is likely to buy
Company is likely to sell
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.